大腸がん治療薬の世界市場レポート 2025年

大腸がん治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.8％で275億3,000万米ドルに成長します。予測期間の成長は、個別化治療の増加、患者中心のケアモデル、標的治療の拡大、併用療法の採用、規制の加速に起因すると考えられます。予測期間の主な動向には、免疫療法の進歩、精密医療の進化、併用療法、バイオマーカーの研究と使用、臨床試験の革新が含まれます。

個別化医療に対する需要の高まりが、今後の大腸がん治療薬市場の成長を牽引すると予想されます。個別化医療は精密医療とも呼ばれ、患者の遺伝子、環境、ライフスタイルの個人差を考慮した治療とヘルスケアへのアプローチです。このアプローチは大腸がん（CRC）の治療に革命をもたらし、患者により個別化された効果的な治療を提供しています。特定の遺伝子や分子プロファイルに合わせた研究や薬剤開発が進むにつれて、CRC治療薬市場の成長は今後も続くと思われます。例えば、2024年2月、米国の非営利団体である個別化医療連合（Personalized Medicine Coalition）は、FDAが2023年に希少疾患患者向けに16の新しい個別化治療を承認したと報告し、2022年に承認された6つから大幅に増加しました。このため、個別化医療に対する需要の高まりが大腸がん治療薬市場の拡大を牽引しています。

また、大腸がん治療薬市場は、臨床試験の増加による成長も見込まれています。臨床試験は、大腸がん治療薬を含む様々な治療法の安全性と有効性を評価するものです。これらの臨床試験は、患者の予後を改善する新規治療法を特定する上で重要な役割を果たし、新薬を市場に投入する可能性もあります。2023年5月にXtalksが報告したように、臨床試験数は452,000件以上登録され、64,000件以上が積極的に参加者を募集しており、2021年初頭に比べて大幅に増加しています。この臨床試験の急増が大腸がん治療薬市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界大腸がん治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の大腸がん治療薬市場：成長率分析
• 世界の大腸がん治療薬市場の実績：規模と成長, 2019-2024
• 世界の大腸がん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界大腸がん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の大腸がん治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血管内皮増殖因子（VEGF）阻害剤
• 上皮成長因子受容体（EGFR）阻害剤
• プログラム細胞死タンパク質1またはPD1リガンド 1（PD1またはPDL1）阻害剤
• BRAFまたはMEK阻害剤
• チロシンキナーゼ（TKI）阻害剤
• 免疫調節薬
• 世界の大腸がん治療薬市場：クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫療法
• 化学療法
• その他のクラス
• 世界の大腸がん治療薬市場流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他の流通チャネル
• 世界の大腸がん治療薬市場血管内皮増殖因子（VEGF）阻害剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベバシズマブ
• ラムシルマブ
• その他のVEGF阻害剤
• 世界の大腸がん治療薬市場上皮成長因子受容体（EGFR）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• セツキシマブ
• パニツムマブ
• その他のEGFR阻害剤
• 世界の大腸がん治療薬市場プログラム細胞死タンパク質1またはPD1リガンド 1（PD1またはPDL1）阻害剤のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• ペムブロリズマブ
• ニボルマブ
• その他のPD1またはPDL1阻害剤
• 世界の大腸がん治療薬市場BRAFまたはMEK阻害剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベムラフェニブ
• エンコラフェニブ
• トラメチニブ
• 世界の大腸がん治療薬市場チロシンキナーゼ（TKI）阻害剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• レゴラフェニブ
• ソラフェニブ
• その他のTKI阻害剤
• 世界の大腸がん治療薬市場、免疫調節剤のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• チェックポイント阻害剤
• その他の免疫調節剤

第7章 地域別・国別分析

• 世界の大腸がん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の大腸がん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 大腸がん治療薬市場：競合情勢
• 大腸がん治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Amgen Inc.
• Astellas Pharma Inc.
• Servier Laboratories
• Eisai Co. Ltd.
• Sumitomo Dainippon Pharma Co. Ltd.
• Ipsen SA
• Taiho Pharmaceutical Co. Ltd.
• Kyowa Kirin Co. Ltd.
• Taiho Oncology Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 大腸がん治療薬市場2029：新たな機会を提供する国
• 大腸がん治療薬市場2029：新たな機会を提供するセグメント
• 大腸がん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Colorectal cancer (CRC) or bowel cancer is a form of cancer that affects the large intestine and the rectum. Depending on their origin, these cancers are referred to as either colon tumors or rectal cancer.

The main types of drugs used for colorectal cancer treatment include vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, programmed cell death protein 1/PD1 ligand 1 (PD1/PDL1) inhibitors, BRAF or MEK inhibitors, tyrosine kinase (TKI) inhibitors, and immunomodulators. Vascular endothelial growth factor (VEGF) inhibitors are drugs that block VEGF and VEGFR activity. The different classes of drugs include immunotherapy, chemotherapy, and others, and these medications are typically dispensed through hospital pharmacies, retail pharmacies, and other distribution channels.

The colorectal cancer drugs market research report is one of a series of new reports from The Business Research Company that provides colorectal cancer drugs market statistics, including colorectal cancer drugs industry global market size, regional shares, competitors with a colorectal cancer drugs market share, detailed colorectal cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the colorectal cancer drugs industry. This colorectal cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The colorectal cancer drugs market size has grown strongly in recent years. It will grow from $20.71 billion in 2024 to $21.98 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to integration of multimodal approaches, introduction of chemotherapy, advancements in surgical techniques, emergence of targeted therapies, clinical trials and research.

The colorectal cancer drugs market size is expected to see strong growth in the next few years. It will grow to $27.53 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to rise in personalized treatment, patient-centric care models, expansion of targeted therapies, adoption of combination therapies, regulatory acceleration. Major trends in the forecast period include immunotherapy advancements, precision medicine evolution, combination therapies, biomarker research and use, clinical trials innovation.

The rising demand for personalized medicines is expected to drive the growth of the colorectal cancer drugs market in the future. Personalized medicine, also known as precision medicine, is an approach to medical treatment and healthcare that considers individual differences in patients' genes, environments, and lifestyles. This approach is revolutionizing the treatment of colorectal cancer (CRC), providing more individualized and effective care for patients. As research and drug development become increasingly tailored to specific genetic and molecular profiles, it is likely to continue propelling the growth of the CRC drug market. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, a significant rise from the six approved in 2022. Therefore, the growing demand for personalized medicine is driving the expansion of the colorectal cancer drugs market.

The colorectal cancer drugs market is also expected to witness growth due to the escalating number of clinical trials. Clinical trials, involving human volunteers, evaluate the safety and efficacy of various medical treatments, including drugs designed for colorectal cancer treatment. These trials play a crucial role in identifying novel therapies that can enhance patient outcomes, potentially introducing new drugs to the market. The substantial increase in the number of clinical trials, with over 452,000 registered studies and more than 64,000 actively seeking participants, as reported by Xtalks in May 2023, indicates a significant rise compared to early 2021. This surge in clinical trials is contributing to the growth of the colorectal cancer drugs market.

Major companies in the colorectal cancer drugs market are focused on gaining FDA approvals for new drugs to enhance profitability. An example is LONSURF (trifluridine/tipiracil), an oral prescription medication approved by the FDA for treating specific cancers such as colon, rectal, and stomach cancer that has metastasized. Taiho Pharmaceutical Co. Ltd. announced FDA approval for LONSURF in combination with bevacizumab for treating metastatic colorectal cancer in August 2023. The combination significantly increased overall and progression-free survival compared to LONSURF alone.

In October 2023, the Bristol-Myers Squibb Company acquired Mirati Therapeutics Inc for $5.8 billion. This strategic move aimed to add KRAZATI, a prominent lung cancer drug, to Bristol Myers Squibb's commercial portfolio, enhancing and diversifying its oncology offerings. The acquisition aligns with Bristol-Myers Squibb's mission to uncover scientific advancements that promise a life free from cancer. Mirati Therapeutics Inc., a US-based biotech company, contributes valuable therapies to Bristol-Myers Squibb's efforts in the field of oncology.

Major companies operating in the colorectal cancer drugs market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Servier Laboratories, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Ipsen SA, Taiho Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Taiho Oncology Inc., Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Mundipharma International Limited, Teva Pharmaceutical Industries Ltd., Gilead Sciences Inc., Johnson & Johnson Services Inc., Spectrum Pharmaceuticals Inc., Exelixis Inc., Seattle Genetics Inc., Incyte Corporation, Clovis Oncology Inc., Karyopharm Therapeutics Inc.

North America was the largest region in the colorectal cancer drugs market in 2024. The Middle East is expected to be the fastest-growing region in the global colorectal cancer drugs market share during the forecast period. The regions covered in the colorectal cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the colorectal cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The colorectal cancer drugs market consists of sales of avastin, bevacizumab, and camptosar. Values in the colorectal cancer drugs market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Colorectal Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on colorectal cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for colorectal cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The colorectal cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Vascular Endothelial Growth Factor (VEGF) Inhibitors; Epidermal Growth Factor Receptor (EGFR) Inhibitors; Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors; BRAF Or MEK Inhibitors; Tyrosine Kinase (TKI) Inhibitors; Immunomodulators
• 2) By Class: Immunotherapy; Chemotherapy; Other Classes
• 3) By Distribution Channels: Hospitals Pharmacies; Retail Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Vascular Endothelial Growth Factor (VEGF) Inhibitors: Bevacizumab; Ramucirumab; Other VEGF Inhibitors
• 2) By Epidermal Growth Factor Receptor (EGFR) Inhibitors: Cetuximab; Panitumumab; Other EGFR Inhibitors
• 3) By Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors: Pembrolizumab; Nivolumab; Other PD1 Or PDL1 Inhibitors
• 4) By BRAF Or MEK Inhibitors: Vemurafenib; Encorafenib; Trametinib; Other BRAF Or MEK Inhibitors
• 5) By Tyrosine Kinase (TKI) Inhibitors: Regorafenib; Sorafenib; Other TKI Inhibitors
• 6) By Immunomodulators: Checkpoint Inhibitors; Other Immunomodulating Agents
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Colorectal Cancer Drugs Market Characteristics

3. Colorectal Cancer Drugs Market Trends And Strategies

4. Colorectal Cancer Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Colorectal Cancer Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Colorectal Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Colorectal Cancer Drugs Market Growth Rate Analysis
• 5.4. Global Colorectal Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Colorectal Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Colorectal Cancer Drugs Total Addressable Market (TAM)

6. Colorectal Cancer Drugs Market Segmentation

• 6.1. Global Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vascular Endothelial Growth Factor (VEGF) Inhibitors
• Epidermal Growth Factor Receptor (EGFR) Inhibitors
• Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors
• BRAF Or MEK Inhibitors
• Tyrosine Kinase (TKI) Inhibitors
• Immunomodulators
• 6.2. Global Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunotherapy
• Chemotherapy
• Other Classes
• 6.3. Global Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals Pharmacies
• Retail Pharmacies
• Other Distribution Channels
• 6.4. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Vascular Endothelial Growth Factor (VEGF) Inhibitorsm, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bevacizumab
• Ramucirumab
• Other VEGF Inhibitors
• 6.5. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Epidermal Growth Factor Receptor (EGFR) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cetuximab
• Panitumumab
• Other EGFR Inhibitors
• 6.6. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pembrolizumab
• Nivolumab
• Other PD1 Or PDL1 Inhibitors
• 6.7. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of BRAF Or MEK Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vemurafenib
• Encorafenib
• Trametinib
• 6.8. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Tyrosine Kinase (TKI) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Regorafenib
• Sorafenib
• Other TKI Inhibitors
• 6.9. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Immunomodulators, By type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Checkpoint Inhibitors
• Other Immunomodulating Agents

7. Colorectal Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Colorectal Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Colorectal Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Colorectal Cancer Drugs Market

• 8.1. Asia-Pacific Colorectal Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Colorectal Cancer Drugs Market

• 9.1. China Colorectal Cancer Drugs Market Overview
• 9.2. China Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Colorectal Cancer Drugs Market

• 10.1. India Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Colorectal Cancer Drugs Market

• 11.1. Japan Colorectal Cancer Drugs Market Overview
• 11.2. Japan Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Colorectal Cancer Drugs Market

• 12.1. Australia Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Colorectal Cancer Drugs Market

• 13.1. Indonesia Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Colorectal Cancer Drugs Market

• 14.1. South Korea Colorectal Cancer Drugs Market Overview
• 14.2. South Korea Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Colorectal Cancer Drugs Market

• 15.1. Western Europe Colorectal Cancer Drugs Market Overview
• 15.2. Western Europe Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Colorectal Cancer Drugs Market

• 16.1. UK Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Colorectal Cancer Drugs Market

• 17.1. Germany Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Colorectal Cancer Drugs Market

• 18.1. France Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Colorectal Cancer Drugs Market

• 19.1. Italy Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Colorectal Cancer Drugs Market

• 20.1. Spain Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Colorectal Cancer Drugs Market

• 21.1. Eastern Europe Colorectal Cancer Drugs Market Overview
• 21.2. Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Colorectal Cancer Drugs Market

• 22.1. Russia Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Colorectal Cancer Drugs Market

• 23.1. North America Colorectal Cancer Drugs Market Overview
• 23.2. North America Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Colorectal Cancer Drugs Market

• 24.1. USA Colorectal Cancer Drugs Market Overview
• 24.2. USA Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Colorectal Cancer Drugs Market

• 25.1. Canada Colorectal Cancer Drugs Market Overview
• 25.2. Canada Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Colorectal Cancer Drugs Market

• 26.1. South America Colorectal Cancer Drugs Market Overview
• 26.2. South America Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Colorectal Cancer Drugs Market

• 27.1. Brazil Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Colorectal Cancer Drugs Market

• 28.1. Middle East Colorectal Cancer Drugs Market Overview
• 28.2. Middle East Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Colorectal Cancer Drugs Market

• 29.1. Africa Colorectal Cancer Drugs Market Overview
• 29.2. Africa Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Colorectal Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Colorectal Cancer Drugs Market Competitive Landscape
• 30.2. Colorectal Cancer Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Colorectal Cancer Drugs Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. F. Hoffmann-La Roche Ltd.
• 31.6. Eli Lilly and Company
• 31.7. Amgen Inc.
• 31.8. Astellas Pharma Inc.
• 31.9. Servier Laboratories
• 31.10. Eisai Co. Ltd.
• 31.11. Sumitomo Dainippon Pharma Co. Ltd.
• 31.12. Ipsen SA
• 31.13. Taiho Pharmaceutical Co. Ltd.
• 31.14. Kyowa Kirin Co. Ltd.
• 31.15. Taiho Oncology Inc.

32. Global Colorectal Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Colorectal Cancer Drugs Market

34. Recent Developments In The Colorectal Cancer Drugs Market

35. Colorectal Cancer Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Colorectal Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Colorectal Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Colorectal Cancer Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer